9 completed, 4 terminated. 13 Phase 2, 5 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 9, Terminated 4 |
| Phase 1 | 5 | Completed 4, Terminated 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow mecasermin: new trials by email Literature Review of mecasermin trials Research Report on mecasermin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency Increlex - Short Stature | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 7 | 2015-12-21 | 2024-02-28 |
| A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder IGF-1, Placebo/saline - Autism Spectrum Disorder | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 3 | 2014-05-01 | 2024-02-08 |
| Treatment of Rett Syndrome With Recombinant Human IGF-1 Recombinant Human Insulin Growth Factor 1 (rhIGF-1), Placebo - Rett Syndrome | Phase 2 | Completed | Boston Children's Hospital | 30 | 2013-01-01 | 2018-03-26 |
| Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome) Insulin-Like Growth Factor-1 (IGF-1), Normal saline - 22q13 Deletion Syndrome, Phelan-McDermid Syndrome | Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 19 | 2012-02-01 | 2022-05-12 |
| Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack mecasermin, 0.9% sodium chloride injection - Heart Failure, Myocardial Infarction | Phase 1 / Phase 2 | Completed | University College Cork | 47 | 2011-10-01 | 2017-03-30 |
| Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy IGF-1 - Duchenne Muscular Dystrophy | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 44 | 2010-11-01 | 2021-01-20 |
| Effect of Increlex® on Children With Crohn Disease rhIGF (Increlex) - Crohn Disease | Phase 2 / Phase 3 | Terminated | Nationwide Children's Hospital | 3 | 2008-10-01 | 2018-03-02 |
| rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]) - Insulin-like Growth Factor-1 Deficiency | Phase 2 | Terminated | Ipsen | 106 | 2007-12-01 | 2023-03-30 |
| Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1 Increlex - Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID) | Phase 1 / Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 6 | 2007-06-01 | 2015-07-03 |
| Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents RhIGF-1 - Anorexia Nervosa | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 16 | 2007-03-01 | 2021-11-18 |
| Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency rhIGF-1 (mecasermin) for a period of 86 weeks - Insulin-Like Growth Factor-1 Deficiency, Growth Disorders | Phase 2 / Phase 3 | Completed | Ipsen | 45 | 2005-07-01 | 2020-07-27 |
| A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients rhIGF-1 (CEP-151) - Multiple Sclerosis | Phase 2 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 15 | 1997-07-01 | 2008-03-04 |
| Long-Term Treatment With rhIGF-1 in GHIS mecasermin - Growth Hormone Insensitivity Syndrome | Phase 2 / Phase 3 | Completed | Ipsen | 92 | 1991-05-20 | 2023-07-06 |
Autism Spectrum Disorder (2) · Anorexia Nervosa (1) · Autistic Disorder (1) · Crohn Disease (1) · Dwarfism (1) · Failure to Thrive (1) · Growth Disorders (1) · Heart Failure (1) · Inflammatory Bowel Diseases (1) · Insulin-Like Growth Factor I Deficiency (1) · Laron Syndrome (1) · Multiple Sclerosis (1) · Muscular Dystrophy, Duchenne (1) · Myocardial Infarction (1) · Puberty, Delayed (1)
Ipsen (3) · Children's Hospital Medical Center, Cincinnati (2) · Icahn School of Medicine at Mount Sinai (2) · Boston Children's Hospital (1) · Massachusetts General Hospital (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Nationwide Children's Hospital (1) · University College Cork (1)
United States (11) · Ireland (1) · Netherlands (1)
Alexander Kolevzon, MD (2) · Dana S. Hardin, MD (1) · Gajanathan Muthuvel, MD (1) · Madhu Misra (1) · Meilan Rutter, MD (1) · Mustafa Sahin, MD, PhD (1) · Noel Caplice, MB, PhD (1) · Philippe Backeljauw, MD (1) · Suk S De Ravin, M.D. (1)
PMID 17192294, PMID 25685306, PMID 29029190, PMID 35395866, PMID 36646053, PMID 37811711, PMID 40351246
2019 (2), R34MH100276 (1)